Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reintroduction of platinum-based therapy after trabectedin in platinum-resistant relapsed ovarian cancer
2014-004020-21Phase 2Completed
- Sponsor
- Fundación para la Investigación Biomédica del Hospital Clínico San Carlos
- Start
- Jan 2015
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trabectedin in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC), primary peritoneal cancer (PPC) and 1 more, sponsored by Fundación para la Investigación Biomédica del Hospital Clínico San Carlos. Primary endpoints: Objective response rate, Time to pathology progression (TTP) and 1 more. Started Jan 2015; status: completed.
02
Drugs
trabectedin
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)ovarian cancer
Beyond the preview
Go deeper on 2014-004020-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004020-21.